Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Kodiak Sciences Inc. (KOD)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/17/2023 |
8-K
| Quarterly results |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Quarterly results|
Docs:
|
"Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Operating expenses Research and development $ 66,961 $ 73,744 $ 123,481 $ 149,921 General and administrative 17,871 18,324 35,966 37,914 Total operating expenses 84,832 92,068 159,447 187,835 Loss from operations Interest income 4,683 1,494 8,300 1,570 Interest expense Other income , net 187 Net loss $ $ $ $ Net loss per common share, basic and diluted $ $ $ $ Weighted-average shares of common stock outstanding used in computing net loss per common share, basic and diluted 52,378,729 52,218,773 52,358,279 52,195,972 Kodiak Sciences Inc. Condensed Consolidated Balance Sheet Data June 30, 2023 December 31, 2022 Cash, cash equivalents and marketable securities $ 378,670 $ 478,933 Working capital $ 312,717 $ 433,50..." |
|
| 07/24/2023 |
8-K
| Quarterly results |
| 07/05/2023 |
4
| BAKER BROS. ADVISORS LP (10% Owner) has filed a Form 4 on Kodiak Sciences Inc.|
Txns:
| Granted 40,000 options to buy
@ $6.9, valued at
$276k
|
|
| 07/03/2023 |
4
| Yang Taiyin (Director) has filed a Form 4 on Kodiak Sciences Inc.|
Txns:
| Granted 40,000 options to buy
@ $6.9, valued at
$276k
|
|
| 07/03/2023 |
4
| PROFUSEK ROBERT (Director) has filed a Form 4 on Kodiak Sciences Inc.|
Txns:
| Granted 40,000 options to buy
@ $6.9, valued at
$276k
|
|
| 07/03/2023 |
4
| Levy Richard S (Director) has filed a Form 4 on Kodiak Sciences Inc.|
Txns:
| Granted 40,000 options to buy
@ $6.9, valued at
$276k
|
|
| 07/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/16/2023 |
4
| EHRLICH JASON (See Remarks) has filed a Form 4 on Kodiak Sciences Inc.|
Txns:
| Sold 1,132 shares
@ $9.42, valued at
$10.7k
Sold 2,258 shares
@ $9.23, valued at
$20.8k
Exercised 3,619 restricted stock units
@ $0
Exercised 1,875 restricted stock units
@ $0 |
|
| 06/16/2023 |
4
| BORGESON JOHN A. (See Remarks) has filed a Form 4 on Kodiak Sciences Inc.|
Txns:
| Sold 1,448 shares
@ $9.42, valued at
$13.6k
Sold 2,749 shares
@ $9.23, valued at
$25.4k
Exercised 3,619 restricted stock units
@ $0
Exercised 1,875 restricted stock units
@ $0 |
|
| 06/07/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/18/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 05/15/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 04/25/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/25/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/25/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/31/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 03/28/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/28/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/28/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
SC 13G/A
| PRICE T ROWE ASSOCIATES INC reports a 0.9% stake in KODIAK SCIENCES INC |
| 02/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 3.2% stake in Kodiak Sciences Inc. |
| 02/03/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 11/09/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/09/2022 |
8-K
| Quarterly results |
| 08/09/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/09/2022 |
8-K
| Quarterly results|
Docs:
|
"Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Operating expenses Research and development $ 73,744 $ 45,404 $ 149,921 $ 85,741 General and administrative 18,324 10,505 37,914 20,726 Total operating expenses 92,068 55,909 187,835 106,467 Loss from operations Interest income 1,135 81 1,211 230 Interest expense Other income , net 310 297 Net loss $ $ $ $ Net loss per common share, basic and diluted $ $ $ $ Weighted-average common shares outstanding used in computing net loss per common share, basic and diluted 52,218,773 51,573,894 52,195,972 51,644,946 Kodiak Sciences Inc. Condensed Consolidated Balance Sheet Data June 30, 2022 December 31, 2021 Cash, cash equivalents and marketable securities $ 597,876 $ 731,510 Working capital $ 534,536 $ 670,128 Total asse..." |
|
| 08/08/2022 |
8-K
| Quarterly results |
| 07/08/2022 |
4
| EHRLICH JASON (See Remarks) has filed a Form 4 on Kodiak Sciences Inc.|
Txns:
| Granted 142,500 options to buy
@ $8.15, valued at
$1.2M
|
|
| 07/08/2022 |
4
| BORGESON JOHN A. (See Remarks) has filed a Form 4 on Kodiak Sciences Inc.|
Txns:
| Granted 142,500 options to buy
@ $8.15, valued at
$1.2M
|
|
| 07/08/2022 |
4
| PERLROTH VICTOR (Chairman and CEO) has filed a Form 4 on Kodiak Sciences Inc.|
Txns:
| Granted 325,000 options to buy
@ $8.15, valued at
$2.6M
|
|
| 07/05/2022 |
4
| Yang Taiyin (Director) has filed a Form 4 on Kodiak Sciences Inc.|
Txns:
| Granted 25,000 options to buy
@ $7.64, valued at
$191k
|
|
|
|
|